Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oligodendrogliomas: an update on basic and clinical research.

Marc Sanson1, Lucinda Aguirre-Cruz, Stéphanie Cartalat-Carel

  • 1Inserm U495 and Fédération de Neurologie Mazarin, Hopital de la Salpetriére, 47 Boulevard de l'Hopital, 75013 Paris, France. m.sanson@psl.ap-hop-paris.fr

Current Neurology and Neuroscience Reports
|April 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiological and FDG-PET imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas.

Journal of neurology·2026
Same author

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

CAR T-Cell Therapy in Patients With Primary Central Nervous System Lymphoma: A LOC Network Study.

American journal of hematology·2026
Same author

Prognostic factors in adult patients with medulloblastoma.

Neuro-oncology practice·2026
Same author

18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Consolidation radiotherapy for primary CNS lymphoma: The lower, the better.

Neuro-oncology·2025

Oligodendrogliomas are now recognized as chemosensitive, but diagnosis remains challenging. New genetic markers like 1p/19q loss are improving classification and treatment for these brain tumors.

Area of Science:

  • Neuro-oncology
  • Molecular Pathology

Background:

  • Oligodendrogliomas are increasingly recognized as chemosensitive gliomas.
  • Histologic diagnosis is subjective, leading to controversy and an unsatisfactory classification.
  • Expanded diagnostic criteria suggest a higher prevalence than previously thought.

Purpose of the Study:

  • To explore new diagnostic markers for oligodendroglial tumors.
  • To investigate the role of genetic markers in predicting prognosis and treatment response.
  • To refine the classification and therapeutic strategies for oligodendroglial tumors.

Main Methods:

  • Utilizing novel oligodendrocytic lineage markers, such as the OLIG1/2 gene.
  • Analyzing genetic markers, specifically chromosomal deletions of 1p and 19q.

Related Experiment Videos

  • Correlating molecular findings with clinical outcomes.

    • Main Results:

    • Emerging lineage markers like OLIG1/2 show promise in defining the spectrum of oligodendroglial tumors.
    • Loss of 1p and 19q chromosomes is a significant predictor of prognosis and treatment response.
    • These genetic markers aid in distinguishing tumor subtypes with different prognoses.

    Conclusions:

    • New molecular and genetic markers are crucial for accurate oligodendroglioma classification.
    • 1p/19q chromosomal status is vital for predicting patient outcomes and guiding therapy.
    • Advancements in molecular diagnostics will significantly improve clinical management of oligodendroglial tumors.